Thelansis’s "Cerebral Vasospasm (CVS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cerebral Vasospasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Cerebral vasospasm is a delayed complication following aneurysmal subarachnoid hemorrhage, characterized by pathological macrovascular narrowing driven by subarachnoid blood breakdown products like oxyhemoglobin. Developing 3 to 14 days post-hemorrhage with a peak at day 7, vasospasm serves as a key driver of delayed cerebral ischemia. Patients present with fluctuating focal neurological deficits or altered consciousness. Diagnosis integrates transcranial Doppler showing elevated flow velocities, CT perfusion, and digital subtraction angiography as the definitive gold standard. Oral nimodipine remains the baseline global standard for delayed cerebral ischemia risk reduction, though it acts primarily via neuroprotection rather than reversing macrovascular narrowing. For targeted vasospasm reduction, standard protocols in select international markets utilize clazosentan, an intravenous endothelin-A receptor antagonist that directly blocks smooth muscle vasoconstriction. ICU management enforces targeted euvolemia and tailored cerebral perfusion pressures, completely replacing historical hypervolemia protocols to avoid pulmonary edema. Refractory, symptomatic arterial narrowing that fails medical optimization is managed with endovascular balloon angioplasty or intra-arterial vasodilator infusions. Prognosis depends entirely on preventing secondary ischemic infarction through vigilant neurocritical monitoring.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Cerebral Vasospasm (CVS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Cerebral Vasospasm (CVS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.